Search

Your search keyword '"Landolfi, Victoria"' showing total 28 results
Start Over Author "Landolfi, Victoria"
28 results on '"Landolfi, Victoria"'

2. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models

Author

Kalnin, Kirill V., Plitnik, Timothy, Kishko, Michael, Zhang, Jinrong, Zhang, Donghui, Beauvais, Adrien, Anosova, Natalie G., Tibbitts, Tim, DiNapoli, Josh, Ulinski, Gregory, Piepenhagen, Peter, Cummings, Sheila M., Bangari, Dinesh S., Ryan, Susan, Huang, Po-Wei D., Huleatt, James, Vincent, Deanne, Fries, Katherine, Karve, Shrirang, Goldman, Rebecca, Gopani, Hardip, Dias, Anusha, Tran, Khang, Zacharia, Minnie, Gu, Xiaobo, Boeglin, Lianne, Abysalh, Jonathan, Vargas, Jorel, Beaulieu, Angela, Shah, Monic, Jeannotte, Travis, Gillis, Kimberly, Chivukula, Sudha, Swearingen, Ron, Landolfi, Victoria, Fu, Tong-Ming, DeRosa, Frank, and Casimiro, Danilo

Published
2021
Full Text
View/download PDF

3. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza

Author

Chivukula, Sudha, Plitnik, Timothy, Tibbitts, Timothy, Karve, Shrirang, Dias, Anusha, Zhang, Donghui, Goldman, Rebecca, Gopani, Hardip, Khanmohammed, Asad, Sarode, Ashish, Cooper, Dustin, Yoon, Heesik, Kim, Younghoon, Yan, Yanhua, Mundle, Sophia T., Groppo, Rachel, Beauvais, Adrien, Zhang, Jinrong, Anosova, Natalie G., Lai, Charles, Li, Lu, Ulinski, Gregory, Piepenhagen, Peter, DiNapoli, Joshua, Kalnin, Kirill V., Landolfi, Victoria, Swearingen, Ron, Fu, Tong-Ming, DeRosa, Frank, and Casimiro, Danilo

Published
2021
Full Text
View/download PDF

4. Reply to Skowronski et al

Author

DiazGranados, Carlos A., Dunning, Andrew J., Robertson, Corwin A., Talbot, H. Keipp, Landolfi, Victoria, and Greenberg, David P.

Published
2016

6. Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model

Author

Kalnin, Kirill V., Plitnik, Timothy, Kishko, Michael, Huang, Dean, Raillard, Alice, Piolat, Julie, Anosova, Natalie G., Tibbitts, Timothy, DiNapoli, Joshua, Karve, Shrirang, Goldman, Rebecca, Gopani, Hardip, Dias, Anusha, Tran, Khang, Zacharia, Minnie, Gu, Xiaobo, Boeglin, Lianne, Abysalh, Jonathan, Vargas, Jorel, Beaulieu, Angela, Shah, Monic, Jeannotte, Travis, Gillis, Kimberly, Chivukula, Sudha, Swearingen, Ron, Landolfi, Victoria, Fu, Tong-Ming, DeRosa, Frank, and Casimiro, Danilo

Subjects
Primates, Cynomolgus macaques, COVID-19 Vaccines, General Veterinary, General Immunology and Microbiology, SARS-CoV-2, Vaccination, SARS-CoV-1, Variants, Public Health, Environmental and Occupational Health, COVID-19, Beta, Antibodies, Viral, Antibodies, Neutralizing, Article, Booster, mRNA vaccine, Neutralization, Infectious Diseases, Delta, Spike Glycoprotein, Coronavirus, Animals, Humans, Molecular Medicine
Abstract

The emergence of SARS-CoV-2 variants, especially Beta and Delta, has raised concerns about the reduced protection from previous infection or vaccination based on the original Wuhan-Hu-1 (D614) virus. To identify promising regimens for inducing neutralizing titers towards new variants, we evaluated monovalent and bivalent mRNA vaccines either as primary vaccination or as a booster in nonhuman primates (NHPs). Two mRNA vaccines, D614-based MRT5500 and Beta-based MRT5500β, tested in sequential regimens or as a bivalent combination in naïve NHPs produced modest neutralizing titers to heterologous variants. However, when mRNA vaccines were administered as a booster to pre-immune NHPs, we observed a robust increase in neutralizing titers with expanded breadth towards all tested variants, and notably SARS-CoV-1. The breadth of the neutralizing response was independent of vaccine sequence or modality, as we further showed either MRT5500 or recombinant subunit Spike protein (with adjuvant) can serve as boosters to induce broadly neutralizing antibodies in the NHPs primed with MRT5500. The data support the notion that a third vaccination is key to boosting existing titers and improving the breadth of antibodies to address variants of concern, including those with an E484K mutation in the Receptor Binding Domain (RBD) (Beta, Gamma).

Published
2022

14. Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates

Author

Kalnin, Kirill V., primary, Plitnik, Timothy, additional, Kishko, Michael, additional, Zhang, Jinrong, additional, Zhang, Donghui, additional, Beauvais, Adrien, additional, Anosova, Natalie G., additional, Tibbitts, Timothy, additional, DiNapoli, Joshua M., additional, Huang, Po-Wei D., additional, Huleatt, James, additional, Vincent, Deanne, additional, Fries, Katherine, additional, Karve, Shrirang, additional, Goldman, Rebecca, additional, Gopani, Hardip, additional, Dias, Anusha, additional, Tran, Khang, additional, Zacharia, Minnie, additional, Gu, Xiaobo, additional, Boeglin, Lianne, additional, Chivukula, Sudha, additional, Swearingen, Ron, additional, Landolfi, Victoria, additional, Fu, Tong-Ming, additional, DeRosa, Frank, additional, and Casimiro, Danilo, additional

Published
2020
Full Text
View/download PDF

26. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age

Author

Gorse, Geoffrey J., primary, Falsey, Ann R., additional, Johnson, Carol M., additional, Morrison, Dennis, additional, Fried, David L., additional, Ervin, John E., additional, Greenberg, David P., additional, Ozol-Godfrey, Ayca, additional, Landolfi, Victoria, additional, and Tsang, Peter H., additional

Published
2013
Full Text
View/download PDF

28. Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

Author

Dunning, Andrew J., DiazGranados, Carlos A., Voloshen, Timothy, Hu, Branda, Landolfi, Victoria A., and Talbot, H. Keipp

Abstract

ABSTRACTAlthough a number of studies have investigated and quantified immune correlates of protection against influenza in adults and children, data on immune protection in the elderly are sparse. A recent vaccine efficacy trial comparing standard-dose with high-dose inactivated influenza vaccine in persons 65 years of age and older provided the opportunity to examine the relationship between values of three immunologic assays and protection against community-acquired A/H3N2 influenza illness. The high-dose vaccine induced significantly higher antibody titers than the standard-dose vaccine for all assays. For the hemagglutination inhibition assay, a titer of 40 was found to correspond with 50% protection when the assay virus was antigenically well matched to the circulating virus—the same titer as is generally recognized for 50% protection in younger adults. A dramatically higher titer was required for 50% protection when the assay virus was a poor match to the circulating virus. With the well-matched virus, some protection was seen at the lowest titers; with the poorly matched virus, high levels of protection were not achieved even at the highest titers. Strong associations were also seen between virus neutralization test titers and protection, but reliable estimates for 50% protection were not obtained. An association was seen between titers of an enzyme-linked lectin assay for antineuraminidase N2 antibodies and protection; in particular, the proportion of treatment effect explained by assay titer in models that included both this assay and one of the other assays was consistently higher than in models that included either assay alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results